1. Current applications and perspectives of diagnostic nuclear medicine in oncology. Task Group of Oncology;Bombardieri;Int. J. Oncol.,1999
2. H. Kolan, J. Li, M. L. Thakur, Sandostatin labeled with 99mTc: In vitro, in vivo validity and comparison with 111In-DTPA-octreotide, Pept. Res. 9 (1996) 144–150.
3. E.P. Krenning, W.H. Bakker, P.P.M. Kooij, W.A.P. Breeman, H.Y. Oei, M. de Jong, J.C. Reubi, T.J. Visser, C. Bruns, D.J. Kwekkeboom, A.E.M. Reijs, P.M. van Hagen P, J.W. Koper, S.W.J. Lamberts, Somatostatin receptor scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-Octreotide, J. Nucl. Med. 33 (1992) 652–658.
4. E.P. Krenning, D.J. Kwekkeboom, W.H. Bakker, W.A.P. Breeman, P.P.M. Kooij, H.Y. Oei, M. van Hagen, P.T.E Postema, M. de Jong, J.C. Reubi, T.J. Visser, A.E.M. Reijs, L.J. Hofland, J.W. Koper, S.W.J. Lambert, Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients, Eur. J. Nucl. Med. 20 (1993) 716–731.
5. D.J. Kwekkeboom, P.P. Kooij, W.H. Bakker, H.R. Macke, E.P. Krenning, Comparison of 11In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: Biodistribution, kinetics, organ and tumor uptake, J. Nucl. Med. 40 (1999) 762–767.